Cargando…

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study

OBJECTIVES: Verinurad (RDEA3170) is a high affinity, selective uric acid transporter (URAT1) inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia. This phase IIa study evaluated the pharmacodynamics, pharmacokinetics and safety of verinurad combined with allopurinol versus allop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleischmann, Roy, Winkle, Peter, Miner, Jeffrey N, Yan, Xiaohong, Hicks, Liz, Valdez, Shakti, Hall, Jesse, Liu, Sha, Shen, Zancong, Gillen, Michael, Hernandez-Illas, Martha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Crystal Arthropathies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845419/ https://www.ncbi.nlm.nih.gov/pubmed/29531784 http://dx.doi.org/10.1136/rmdopen-2017-000584

Ejemplares similares

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout
por: Murdoch, Rachel, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout
por: Kankam, Martin, et al.
Publicado: (2018)

Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study
por: Uhlig, Till, et al.
Publicado: (2023)

Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial
por: Ghang, Byeong-zu, et al.
Publicado: (2022)

Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study
por: Hammer, Hilde Berner, et al.
Publicado: (2022)

Spontaneous resolution of acute gout: mechanisms and therapeutic targets
por: Shi, Meiling, et al.
Publicado: (2023)

Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective
por: Kapetanovic, Meliha C, et al.
Publicado: (2016)

Multiple common and rare variants of ABCG2 cause gout
por: Higashino, Toshihide, et al.
Publicado: (2017)

Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care
por: Roddy, Edward, et al.
Publicado: (2020)

Subtype-specific gout susceptibility loci and enrichment of selection pressure on ABCG2 and ALDH2 identified by subtype genome-wide meta-analyses of clinically defined gout patients
por: Nakayama, Akiyoshi, et al.
Publicado: (2020)

Occupational exposure to inorganic dust and risk of gout: a population-based study
por: Sigurdardottir, Valgerdur, et al.
Publicado: (2020)

Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients
por: te Kampe, Ritch, et al.
Publicado: (2022)

Gout and the risk of incident atrial fibrillation in older adults: a study of US Medicare data
por: Singh, Jasvinder A, et al.
Publicado: (2018)

Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout
por: Kawamura, Yusuke, et al.
Publicado: (2019)

Factors influencing the kinetics of MSU crystal depletion measured with dual-energy CT in patients with gout
por: Laurent, Victor, et al.
Publicado: (2023)

Filling gaps in female gout: a cross-sectional study of comorbidities in 192 037 hospitalised patients
por: Rodríguez-Sosa, Enrique, et al.
Publicado: (2023)

Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease
por: Cipolletta, Edoardo, et al.
Publicado: (2023)

Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality
por: Pérez Ruiz, Fernando, et al.
Publicado: (2019)

Relationship between tissue stress during gait in healthy volunteers and patterns of urate deposition and bone erosion in gout: a biomechanical computational modelling study
por: Dalbeth, Nicola, et al.
Publicado: (2015)

Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink
por: Roddy, Edward, et al.
Publicado: (2023)

12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target
por: Uhlig, Till, et al.
Publicado: (2021)

Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan
por: Koto, Ruriko, et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects
por: Hall, Jesse, et al.
Publicado: (2018)

Diagnostic value of ultrasound in calcium pyrophosphate deposition disease: a systematic review and meta-analysis
por: Gamon, Etienne, et al.
Publicado: (2015)

Tophus resolution with pegloticase: a prospective dual-energy CT study
por: Araujo, Elizabeth G, et al.
Publicado: (2015)

Systematic review and quality analysis of emerging diagnostic measures for calcium pyrophosphate crystal deposition disease
por: Wu, Y, et al.
Publicado: (2016)

Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT
por: Wang, Penny, et al.
Publicado: (2018)

Influence of genetic variants on renal uric acid handling in response to frusemide: an acute intervention study
por: Dalbeth, Nicola, et al.
Publicado: (2017)

Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis
por: Krekeler, Martin, et al.
Publicado: (2022)

Case report: crowned dens syndrome in a patient with seronegative rheumatoid arthritis
por: Ferraccioli, Gianfranco, et al.
Publicado: (2023)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers
por: Hall, Jesse, et al.
Publicado: (2018)

Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study
por: Shiramoto, Masanari, et al.
Publicado: (2018)

Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non‐Asian participants
por: Johansson, Susanne, et al.
Publicado: (2022)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects
por: Shen, Zancong, et al.
Publicado: (2017)

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor
por: Smith, William B., et al.
Publicado: (2018)

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout
por: Tan, Philip K., et al.
Publicado: (2017)

Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers
por: Gillen, Michael, et al.
Publicado: (2016)

The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout
por: Baumgartner, Scott, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0o5ikfkjnc6j28op8tqnu9ehan